Toxicological fate of Artemether-lumefantrine after exposure to enzyme inducer (Phenobarbitone) and inhibitor (Omeprazole) of Cytochrome P450 in Wister rats
Article Sidebar
Main Article Content
Abstract
Background: Due to lack of toxicological fate information of artemether-lumefantrine (AL) after exposure to Cytochrome P450 inducer (phenobarbitone) and inhibitor (omeprazole) this research work was undertaken to assess the AL toxicological fate after exposure to phenobarbitone and omeprazole in Wister rats.
Methods: Phenobarbitone (10 mg/kg) and omeprazole (20 mg/kg) were administered orally to albino rats for twenty-eight days. Artemether-lumefantrine was administered on the day 29, 30 and 31. The rats were euthanized under chloroform anesthesia on day 32. Blood samples collected from abdominal aorta were assessed for toxicity markers such as weights, glucose, lipids, renal electrolytes, liver enzymes and hematological indices.
Results: Out of the thirty-seven toxicity markers assessed, twenty-three showed significant differences (P<0.05). Phenobarbitone and omeprazole increased weight significantly after 14 days and 28 days. Phenobarbitone, omeprazole, artemether-lumefantrine, phenobarbitone-artemether-lumefantrine (PAL) and omeprazole-artemether-lumefantrine (OAL) increased weight between day 28 and 32. Glucose was increased by PAL and OAL. Cholesterol, Triglyceride, High Density Lipoprotein and Low-Density Lipoprotein were significantly decreased by PAL and OAL. Except LDL, other lipids were decreased significantly P<0.05 by AL. Urea, creatinine, and chloride ion increased due to AL and PAL, but decreased by OAL. Alkaline phosphatase, conjugated bilirubin and total bilirubin were altered by PAL and OAL. Eleven haematological indices also changed significantly.
Conclusion: Phenobarbitone and omeprazole altered the toxicological potential of artemether-lumefantrine after exposure. Artemether-lumefantrine may be recommended to be used with caution among patients which are chronic users of phenobarbitone in epilepsy and omeprazole in gastric ulcers.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Tompkins, L.M., Wallace, A.D. Mechanisms of cytochrome P450 induction. Journal. Biochemical and Molecular Toxicology 2007; 21: 176–181.
Aung AK, David W. Haas DW, Hulgan T and Phillips EJ. Pharmacogenomics of antimicrobial agents. Pharmacogenomics 2014;15:15, 1903–1930.
3, Staehli Hodel EM, Csajka C, Ariey F, Guidi M, Kabanywanyi AM, Duong S, Decosterd LA, Olliaro P, Beck HP, Genton B. Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania. Antimicrobial Agents Chemotherapy 2013; 57:2:950-8.
World Health Organization. Antimalarial Drug Combination therapy: Report of a WHO technical consultation, Geneva. World Health Organization, Pp: 1-36. Accessed from:http://www.who.int/malaria/world-malaria-report-2010/en/index.html
Federal Ministry of Health Nigeria (FMOH). National Drug Policy on malaria treatment 2005: 1-20.
Ingelman-Sundberg M, Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future, Trends in Pharmacology Sc 2004; 25:4, 193-200.
Ritter JM, Lewis LD, Mant TG, Ferro AA. Textbook of Clinical Pharmacology and Therapeutics Drug metabolism. 5th Edition 2008. Cap 5.Pp 24-30.
Lin JH and Lu AYH. Inhibition and induction of cytochrome P450 and the clinical implications. Clinical Pharmacokinetics 1998; 35:361-390.
Murray M. Mechanisms and significance of inhibitory drug interactions involving cytochrome P450 enzymes. International Journal of Molecular Medicine 1999;3: 227-238.
Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing duodenal ulcers? Gastroenterology 1990; 99:345-351
Knupp CA and Barbhaiya RH. A multiple-dose pharmacokinetic interaction study between didanosine (Videx) and ciprofloxacine (Cipro) in male subjects seropositive for HIV but asymptomatic. Biopharmaceutic Drug Dispensing 1997; 18: 65-77
Hollenberg PF. Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes. Drug Metabolism Review 2002; 34: 17-35.
Aghahowa SE, Ozolua RI, Bafor EE, Obarisiagbon P and Isah AO. Comparative Safety Profile of Artemisinin-Based Combination Therapies in Patients with Uncomplicated Malaria. Journal Pharmacy and Drug Research 2018; 1:1: 23-27.
Tijani SA, Ukwenya VO, Fakunle JB. Acute administration of co-artemisiane induced oxidativestress in the testes of adult Wistar rats. Bioscience Research Communication Molecules 2011; 22: 5-12.
Oda H, Okuda Y, Yoshida Y, Kimura N, Kakinuma A. Phenobarbital Reduces Blood Glucose and Gluconeogenesis Through Down-Regulation of Phosphoenolpyruvate Carboxykinase (GTP) Gene Expression in Rats. Biochemical and Biophysiological Research Communication 2015; 23:466 (3):306-11.
Barchetta I, Guglielmi C, Bertoccini L, Calella D, Manfrini S, Secchi C, Pozzilli P, Cavallo MG. Therapy with proton pump inhibitors in patients with type 2 diabetes is independently associated with improved glycometabolic control. Acta Diabetology 2015: Epub ahead of print.
Boj-Carceller D, Bocos-Terraz P, Moreno-Vernis M, Sanz-Paris A, Trincado-Aznar P, Albero-Gamboa R. Are proton pump inhibitors a new antidiabetic drug? A cross sectional study. World Journal of Diabetes 2011; 2:217–220.
Mefford IN, Wade EU. Proton pump inhibitors as a treatment method for type II diabetes. Medical Hypotheses 2009;73:29–32.
Han N, Oh M, Park SM et al. The Effect of Proton Pump Inhibitors on Glycated Hemoglobin Levelsin Patients with Type 2 Diabetes Mellitus. Canadian Journal of Diabetes 2015; 39: 24e28
Hove KD, Brøns C, Færch K, et al. Effects of 12 weeks’treatment with a protonpump inhibitor on insulin secretion, glucose metabolism and markers of car-diovascular risk in patients with type 2 diabetes: A randomised double-blindprospective placebo-controlled study. Diabetologia 2013; 56:22e30.
Kariuki SM, Ikumi M, Ojal J, et al. Acute seizures attributable to falciparum malaria in an endemic area on the Kenyan coast. Brain 2011; 134:5: 1519–1528.
Ogwang R, Anguzu R, Akun P, et al. Asymptomatic malaria parasitaemia and seizure control in children with nodding syndrome; a cross-sectional study. British Medical Journal 2018; 1-7
Voight BF, Peloso GM, Orho-Melander M, Frikke- Schmidt R, Barbalic M, et al. Plasma HDL cholesterol and risk of myocardial infarction: A Mendelian randomisation study. Lancet 2012, 380: 572-580
Okey, A.B. Enzyme induction in the cytochrome P-450 system. Pharmacology and Therapeutics 1990; 45: 241–298.
25, Makanga M, Premji Z, Falade C, Karbwang J, Mueller EA, Andriano K, Hunt P, De Palacios PI. Efficacy and safety of the six-dose regimen of artemether-lumefantrine in pediatrics with uncomplicated Plasmodium falciparum malaria: a pooled analysis of individual patient data.
American Journal of Tropical Medicine and Hygiene 2006; 74(6):991-8.
Mueller EA, van Vugt M, Kirch W et al. Efficacy and Safety of the Six-Dose Regimen of Artemether-Lumefantrine for Treatment of Uncomplicated Plasmodium Falciparum Malaria in Adolescents and Adults: A Pooled Analysis of Individual Patient Data From Randomized Clinical Trials. Acta Tropica 2006; 100(1-2):41-53.
Mehlotra RK, Ziats MN, Bockarie MJ, Zimmerman PA. Prevalence of CYP2B6 allele in malaria-endemic populations of West Africa and Papua New Guinea. European Journal of Clinical Pharmacology 2006; 62(4):267–275.
Svensson US, Ashton M. Identification of the Human Cytochrome P450 Enzymes Involved in the in Vitro Metabolism of Artemisinin. British Journal of Clinical Pharmacology 1999; 48(4):528-35.
Piedade R, Gil JP. The pharmacogenetics of antimalaria artemisinin combination therapy. Expert Opinion on Drug Metabolism and Toxicology 2011; 7(10): 1185–1200
Kerb R, Fux R, Mörike K, et al. Pharmacogenetics of antimalarial drugs: effect on metabolism and transport. Lancet Infectious Disease 2009; 9(12): 760–774.
Etim OB,Utibe CG Sambo,E and Akpan,E. Toxicological Evaluation of Some Artemisinin Combination Therapies (ACTs)on the Kidney and Liver of Albino Wistar Rats. International Journal of Biochemical Research and Review 2016; 9: 1-5.10.9734/IJBCRR/2016/22846.
Etim EI, Udoh IE, Udoh AE. Evaluation of plasma creatinine and urea after oral administration of Artemisinin and some Artemisinin combination therapy regimen on healthy Nigerian males. World Journal of Applied Science and Technology 2012; 4:1-6.
Grosser T, Smyth E, FitzGerald GA. Anti-inflammatory, anti-pyretic and analgesic agents; pharmacotherapy of gout. In: Goodman and Gilman's Pharmacological Basis of Therapeutics (Eds. BruntonLL, Chabner BA, Knollmann BC) (12th Ed) Cap 34.McGraw-Hill, 2011; Pp: 972.
Maranville JC, Di Rienzo A. Combining geneticand non-genetic biomarkers to realize the promise of pharmacogenomics for inflammatory diseases. Pharmacogenomics 2014; 15: 1931-1940.
Georgewill G, Ebong O. Artemisinin combination therapies: Safe or not safe? International Journal of Pharmacology 2012; 10: 1-6.
Aniefiok U, Edoho JE, Olurufemi E, Etim EI. Effect of artemisinin with folic acid on the activities ofaspartate aminotransferase, alamine aminotransferase and alkaline phosphate in rat. Asian Journal of Biochemistry 2009; 4: 55-59.
Aprioku JS, Obianime AW. Structure activity -Relationship of artemisinin on some biological systemsin male Guinea pigs. Insight of Pharmacy Science 2011; 1: 1-10.
Syed NA, Zaeem AS. Antiepileptic drugs and liver disease. Seizure 2006; 15: 3, 156-164.
Meunier L and Larrey D. Drug-Induced Liver Injury: Biomarkers, Requirements, Candidates, and Validation. Front Pharmacology 2019; 10:1482.
Bhaltacharya M,Western V,Pan K. Elevation of serum/plasma enzymes of acute hepatocellular damage. Clinical Pharmacology and Therapeutics 2003; 41(7):16-19.
Osonuga IO,Osonuga OA, Osonuga A, Onadeko AA, Osonuga AA. Effect of artemether on hematological parameters of healthy and uninfected adult Wistar rats. Asian Pacific Journal Tropical Biomedicine 2012; 2(6): 493-495.
Zhao XJ, Yokoyama H, Chiba K, Wanwimolruk S and Ishizaki. Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human liver microsomes and nine recombinant human cytochromes P450. Journal of Pharmacology and Experimental Therapeutics 1996; 3:1327-1334.
Nebert DW, Wikvall K, Miller W. Human Cytochrome P450 in health and disease. Philosophical and Transactions of the Royal Society of Britain 2013; 368: 2012.0431.
Guengerich FP. Cytochrome P450, Drugs, and diseases. Molecular Interview 2003; 3, issue 4, 194-204.
Lu C and Li AP. Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague-Dawley rat, minipig and beagle dog. Chemical Biology International 2001; 134: 271-281. 135.
Kashfi K, McDougall CJ and Dannenberg AJ. Comparative effects of omeprazole on xenobiotic metabolizing enzymes in the rat and human. Clinical Pharmacology and Therapeutics 1995; 58:625-630.
Kita T, Sakaeda T, Baba T, et al. Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors. Biology and Pharmacy Bulletin 2003; 26(3):386-390.
Ma JD, Lee KC, and Kuo GM. Clinical Application of Pharmacogenomics. Journal of Pharmacy Practice 2012; 25:4: 417-427
Khoo S, Back D, Winstanley P. The potential for interactions between antimalarial and antiretroviral drugs. AIDS 2005;19(10):995–1005.
Aweeka FT, German PI. Clinical pharmacology of artemisinin-based combination therapies. Clinical Pharmacokinetics 2008; 47(2):91–102.
Back D., Gibbons S., Khoo S. Pharmacokinetic drug interactions with nevirapine. Journal of Acquired Immune Deficiency Syndrome 2003;34(Suppl. 1): S8–S14.
White N. Antimalarial drug resistance and combination chemotherapy. Philosophical Trans of the Royal Soc of London. Series B: Biological Science 1999; 354:739-749.